Artiva Biotherapeutics, Inc. · NASDAQ:ARTV
Artiva Biotherapeutics — Investor Presentation (May 2026)
33 slides from Artiva Biotherapeutics's investor presentation, May 2026
Slide 1: Artiva Biotherapeutics
Artiva Biotherapeutics May 2026
Slide 2: Disclaimers and Forward-looking Statements
Disclaimers and Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Statements in this presentation that are not statements of historical fact are forward- looking statements. Such forward-looki
Slide 3: Management Team with Deep Expertise in Cell & Gene Therapy and Autoimmune Disease
Management Team with Deep Expertise in Cell & Gene Therapy and Autoimmune Disease Fred Aslan Subhashis Banerjee Chris Horan Thad Huston Jennifer Bush Heather Raymon Nicholas Veomett CEO CMO CTOO CFO COO SVP Research & VP, Corp Dev Early Development Development Experience Across Multiple Notable Bloc
Slide 4: Opportunity Summary
Opportunity Summary 1 Deep B-cell depletion – potent mechanism vis-à-vis other novel approaches 2 Strategic interest across modalities (auto-CAR-T, TCE, in vivo, allo) 3 Refractory RA – approx. $5B* being spent on patients unlikely to respond after failed 2+ b/tsDMARDs 4 AlloNK activity and tolerabi
Slide 5: Consistent Activity Observed Across Indications
Consistent Activity Observed Across Indications N=14 aNHL, N=24 r/rHL, Over 70 Autoimmunity Patients Initiated Treatment as of end of April 2026 Includes all patients with 3 or more months of follow-up in IIT and Basket Study N = 14 aNHL N = 11 SjD N = 5 SSc N = 21 RA CRR % mDoR (mo) CDAI (change) C
Slide 6: B-Cell Depletion and “Reset” Hypothesis
B-Cell Depletion and “Reset” Hypothesis Role of B cells in autoimmune disease: Autoantibody Rituximab 1 production / tissue damage “Dimming” 2 Antigen “Reset” with naive / transitional presentation / T cell B cell phenotype amplification Cytokine secretion / 3 inflammation Durable benefit Transient
Slide 7: AlloNK: CD16 is a strong cell activating receptor, driving ADCC against B cells
AlloNK: CD16 is a strong cell activating receptor, driving ADCC against B cells 1 AlloNK (NK cell) Supportive CY/FLU 3 conditioning B-cell Rejection X Antigen CD16 Pathogenic • CD8/CD4 rejection c B-cell • NK rejection (missing self) • HLA ab (ADCP- macrophage, ADCC- NK, neutrophils) B-cell targetin
Slide 8: AlloNK + RTX Showed Consistent Complete B-Cell Depletion in Autoimmune Diseases
AlloNK + RTX Showed Consistent Complete B-Cell Depletion in Autoimmune Diseases Uniform and consistent B-cell depletion observed by Day 13 in all B-cell Reconstitution in Patients Treated with AlloNK + 51 patients with autoimmune diseases RTX Consistent with Auto-CAR T Academic Study Opportunity to
Slide 9: AlloNK + RTX Showed Complete B-Cell Depletion Using High Sensitivity Assay
AlloNK + RTX Showed Complete B-Cell Depletion Using High Sensitivity Assay No CD19+ B cells in single tissue RTX-only AlloNK + RTX biopsy case study in RA patient Median level of B-cells (cells/µl) at B-cells (cells/µl) at nadir using Day 28 Synovial Biopsy 2 weeks using high sensitivity assay 1 hig
Slide 10: Incomplete Depletion Likely Leads to Relapse
Incomplete Depletion Likely Leads to Relapse 9 of 15 13 of 15 relapsed relapsed by 3 mos by 6 mos Blinatumomab (CD19 TCE) B-cell depletion in 6 patients with RA1 2 Artiva Biotherapeutics (1) Bucci et al Nat Med 2024 (2) Grieshaber-Bouyer et al 2026 Accelerating Bio-Innovation (ABI) Conference 10
Slide 11: The Unmet Need in RA: Poor Responses in Patients who Failed 2+ b/tsDMARDs
The Unmet Need in RA: Poor Responses in Patients who Failed 2+ b/tsDMARDs b/tsDMARD line 1st 2nd 2nd TNF 3rd and later 100 75 The RA “Ceiling Effect” AlloNK’s goal: ACR50 in ≥50% of refractory RA % of RA patients patients 50 45% achieving 39% ACR50 36% 27% Response 25 23% 20% 19% 11% 13% 0 Upa (JAK)
Slide 12: ~$5B Spent on US RA Patients Who Failed 2+ b/tsDMARDs
~$5B Spent on US RA Patients Who Failed 2+ b/tsDMARDs 1.5M Total Diagnosed U.S. Prevalence [1] Moderate/Severe: 55% [1] Mild: 45%[1] 820k treated w/ csDMARD (e.g. MTX) ~575k treated with b/tsDMARDs [2] US RA market: ~$20B/yr[3-6] 150-200k ~$5B/yr (25%*) spent on Failed 2+ patients with 80-90% chance
Slide 13: AlloNK+RTX Initial Clinical Data in RA: Patient Demographics
AlloNK+RTX Initial Clinical Data in RA: Patient Demographics 21 RA Patients* with 12+ Week Follow-Up # Prior Classes b/tsDMARDs Mean (range) 5 classes 5% 5% 4 Demographics 3 19% Age (yrs) 52.5 (31-76) Female (%) 100% 81% failed 2+ b/tsDMARDs Disease Duration (yrs) 14.8 (1.6-41) 2 52% Disease Activit
Slide 14: CDAI & DAS28-ESR Reduction Observed at 3 or 6 Months
3mo MCII* (≥ 12 for CDAI; 6mo CDAI & DAS28-ESR Reduction Observed at 3 or 6 Months ≥ 1.2 for DAS28) CAR-T IIT Basket Study External Subject RA-2 RA-5 RA-6 RA-3 RA-1 RA-4 RA-11 RA-10* RA-13 RA-8* RA-12 RA-7 RA-9 RA-19 RA-20 RA-21 RA-17 RA-15*RA-18* RA-14 RA-16 Auto CAR-T in RA [1,2] Baseline 36 34 54
Slide 15: CDAI & DAS28 Change from Baseline
CDAI & DAS28 Change from Baseline AlloNK + Ritux: Mean Change from Baseline (+/- SEM) CDAI DAS28-ESR DAS28-CRP (basketϕ) (mean 50.7 baseline) (mean 7.3 baseline) (mean 6.7 baseline) 0 0.0 0.0 -5 -0.5 -0.5 • Rapid improvement in clinical -10 scores, with further reduction -12 -1.0 -1.0 -15 -1.2 -1.2
Slide 16: ACR50 Scoring Using Currently Available ACR Components as Proxy
ACR50 Scoring Using Currently Available ACR Components as Proxy ACR Components ACR50 mACR50 TJC ✓ ✓ SJC ✓ ✓ PtGA ✓ ✓ PhGA ✓ ✓ 2 of 3 ESR or CRP ✓ 3 of 5 HAQ-DI Pain Artiva Biotherapeutics 16
Slide 17: ACR Component Scores
ACR Component Scores AlloNK + Ritux: Mean Change from Baseline (+/- SEM) Swollen Joints (SJC) Tender Joints (TJC) 0 Clinical response (>50% reduction) -10 All Subjects (Avg) -20 12wk f/u only (n=8) -30 -40 -50 -50 • Required for ACR50 Response: ≥ 50% -60 improvement in both SJC and TJC -70 -70 -80 •
Slide 18: High Initial ACR Response Rate Observed at 6 Months
High Initial ACR Response Rate Observed at 6 Months Majority of Component Scores Showed ≥ 70% Improvement ACR Heat-Map at 6 Months: % Change from Baseline ≥50% improvement 83% ACR50/mACR50 in IIT 71% ACR50 in Basket Study Artiva Biotherapeutics mACR50 calculated only for the IIT, where HAQ-DI and Pa
Slide 19: High ACR Response Rate Observed in Refractory RA Patients at 6 Months
High ACR Response Rate Observed in Refractory RA Patients at 6 Months ACR Responses Among RA Patients in Company-Sponsored Basket Study ACR50 ACR20 100% 29% Deep responses, supporting TPP of ≥50% ACR50 at 6 months 33% RCT with more uniform parameters 71% • Patients remain on background meds, up to 1
Slide 20: “Swimmer’s plot” for RA patients
“Swimmer’s plot” for RA patients Months 0 3 6 9 12 15 18 21 RA-1 ✓ AlloNK treatment cycle RA-2 On-study; no steroids beyond “soft RA-3 ✓ rescue”; no new b/tsDMARDs RA-4 ✓ RA-5 ✓ ACR50/mACR50 at 6 months RA-6 ✓ ACR50/mACR50 achieved prior to RA-7 ✓ 6 monthsϕ RA-8 ✓ RA-9 ✓ Loss of response* or study R
Slide 21: Tolerability Profile of AlloNK + RTX Compared to Autologous CAR-T and BCMA T-Cell Engagers
Tolerability Profile of AlloNK + RTX Observed Compared Favorably to Autologous CAR-T and BCMA Targeted T-Cell Engagers Deep B-cell Depletion Datasets AlloNK + Auto CAR-T T-Cell Engager Schett / CASTLE1 teclistamab2 Comparable to Serious Infection ritux Rates for Approved RA therapies3: No. of Patien
Slide 22: Experience in First 55 Autoimmune Patients Treated with AlloNK + RTX
Experience in First 55 Autoimmune Patients Treated with AlloNK + RTX Hospitalization Rates Consistent with mAb Alone Showing Ability to Manage Patients as Outpatient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Outpatient Treatment Day Hospitalization for AE IIT 1 1 No
Slide 23: Neutrophil Counts Returned to Normal by Day 28 in Most RA Subjects
Neutrophil Counts Returned to Normal by Day 28 in Most RA Subjects Absolute Neutrophil Counts in N=30 RA subjects from AB-101-05 and IRIS-RD-01 studies Artiva Biotherapeutics Data cut as of April 3, 2026 23
Slide 24: Illustrative Rethinking of Cell Therapy-like Activity with Biologics-like Ease-of-Use
Illustrative Rethinking of Cell Therapy-like Activity with Biologics-like Ease-of-Use 1 Scalability, $8K COGS 2 Outpatient treatment 3 Low doses of CY/FLU AlloNK® Cumulative (mg/m2) 1B cell vial 4,500 900 450 90 Cy Flu 40 activated sites CLL regimen AlloNK regimen 4 Potential for long-term control o
Slide 25: Registrational Strategy
Registrational Strategy • Single registrational RCT; N = ~150 RA pts with inadequate response to 2+ b/tsDMARDs • Randomized 2:1 to AlloNK + RTX vs. RTX-only • Primary efficacy end point: ACR50 at 6 months • AlloNK dosing: 4B cells x 2 doses (Days 6 and 20) • RTX-only non-responders may cross-over in
Slide 26: Program Commercial Objectives
Program Commercial Objectives “Enough! Time for cell therapy” • To be the first FDA-approved deep B-cell depleting therapy for refractory RA patients who have failed 2+ b/tsDMARDs • To be a one-time treatment (“reset”) lasting more than 18 months with several patients still benefiting 3 years later;
Slide 27: Illustrative Market Reach in US alone
Illustrative Market Reach in US alone 50 clinics in RCT in US 250 clinics x 1-2 patients per month …out of >2,000 rheum …where top HCPs see estimated community clinics with 20-30 2+b/tsDMARD-IR patients infusion chairs [1,2] per month [3,4] Reimbursement framework expected to be in line with other I
Slide 28: Clinical Responses Observed in SjD
Clinical Responses Observed in SjD Min. Point Change for Response ClinESSDAI (change) ESSDAI (change) ESSPRI (change) SSF at 6mo (change) (Mean +/- SEM) (Mean +/- SEM) (Mean +/- SEM) (Mean +/- SEM) Mean 16.1 baseline Mean 13.1 baseline Mean 8.0 baseline Mean 0.65 baseline 0 0 0.0 1.0 -1 -1 0.9 -0.5
Slide 29: Clinical Responses Observed in SjD: Benchmarking
Clinical Responses Observed in SjD Min. Point Change for Response Benchmarking Against Other Emerging Rx in SjD Disease Clin ESSDAI ESSPRI SSF FACIT-F PtGA Duration ESSDAI Mean AlloNK + rtx, 6mo -8.6 -6.6 -3.0 +0.76 +13.0 -44% 12.2yr -5.1 to Ianalumab Ph2 + Ph3, 24wk[1,2] Max 7.5yr - -1.8[2] +0.1[1]
Slide 30: Clinical Responses Observed in Systemic Sclerosis (SSc)
Clinical Responses Observed in Systemic Sclerosis (SSc) Min. Point Change for Response mRSS (change) rCRISS response (Mean +/- SEM) (%) 0 • Mean age 54yrs, 60% male -1 -2 • Mean 4.1yr disease duration -3 50% • Mean baseline mRSS = 19.8 -4 -5 • Resistant to prior immunomodulators -6 100% (incl. 3/5 w
Slide 31: Expected Data and Trial Maturation in RA
Expected Data and Trial Maturation in RA H2’26 H1’27 H2’27 H1’28 H2’28 30+ total pts RA 50+ total pts w/ 18-36 mos f/u • 15+ pts w/ ACR50@6m open-label update: 50+ total pts • 40+ pts w/ ACR50@6m • 20+ pts w/ 12-18+ mos f/u RA RCT Enrollment complete RCT read-out Trial initiation Plans for second in
Slide 32: Road Map to Becoming Potential First-in-Class
Road Map to Becoming Potential First-in-Class ✓ Deep B-cell depletion MoA (low sensitivity + high sensitivity B-cell assay, B-cell reconstitution) ✓ Initial safety profile consistent with desired TPP in community (rheumatologists can “own”) ✓ Unmet need in 2+ b/tsDMARD failure in RA (25% of $20B+ b/
Slide 33: Opportunity Summary
Opportunity Summary 1 Deep B cell depletion - potent mechanism vis-à-vis other novel approaches 2 Strategic interest across modalities (auto-CAR-T, TCE, in vivo, allo) 3 Refractory RA – approx. $5B* being spent on patients unlikely to respond after failed 2+ b/tsDMARDs 4 AlloNK activity and tolerabi
Artiva Biotherapeutics — Investor Presentation (May 2026) on 6ix